Fmr LLC Raises Position in 10x Genomics, Inc. (NASDAQ:TXG)

Fmr LLC increased its position in 10x Genomics, Inc. (NASDAQ:TXG) by 0.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,454,434 shares of the company’s stock after purchasing an additional 86,455 shares during the quarter. Fmr LLC owned 0.11% of 10x Genomics worth $193,206,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Signaturefd LLC increased its stake in 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after purchasing an additional 1,452 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after buying an additional 1,299 shares during the last quarter. Sound Income Strategies LLC boosted its position in 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after acquiring an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in 10x Genomics in the fourth quarter worth about $52,000. Finally, SRS Capital Advisors Inc. boosted its holdings in shares of 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock valued at $70,000 after acquiring an additional 4,324 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Trading Up 4.0 %

Shares of NASDAQ TXG opened at $8.01 on Friday. The company has a market capitalization of $979.64 million, a P/E ratio of -5.27 and a beta of 2.01. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $36.15. The stock has a 50 day moving average of $10.44 and a 200-day moving average of $13.96.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Alan Mateo acquired 40,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The shares were bought at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now directly owns 61,691 shares in the company, valued at $687,237.74. The trade was a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Serge Saxonov sold 5,092 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TXG. Barclays dropped their target price on shares of 10x Genomics from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday. Leerink Partnrs lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. Morgan Stanley lowered their price target on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. UBS Group dropped their price objective on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Finally, Canaccord Genuity Group lowered their target price on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Hold” and a consensus target price of $19.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.